

Supplemental Approvals

Generic Name (Trade Name—Company)

December 31, 2010

Uses/Notes

Prevention of skeletal-related events in patients with bone metastases from solid tumors

Denosumab

(Xgeva—Amgen)

Antibody for bone metastases from solid tumors

Data from three randomized, double-blind trials comparing denosumab 120 mg with zoledronic acid 4 mg (Zometa—Novartis), both given once every 4 weeks, showed that denosumab was superior to zoledronic acid in preventing skeletal-related events in patients with breast or prostate cancer and bone metastasis and was noninferior to zoledronic acid in preventing these events in patients with multiple myeloma or other solid tumors. The [FDA](#)-recommended dose is 120 mg administered as a subcutaneous injection every 4 weeks. It is important to distinguish the dosing and indication differences between Prolia and Xgeva, both of which contain denosumab. Prolia is dosed as a 60-mg subcutaneous injection once every 6 months and is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Source URL:

<http://www.aphanet.org/antibody-bone-metastases-solid-tumors>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.